8.81

3.50% -0.34

Karyopharm Therapeutics Inc (KPTI)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$9.15

Offen:

$9.13

24-Stunden-Volumen:

365.60K

Relative Volume:

0.78

Marktkapitalisierung:

$161.61M

Einnahmen:

$137.27M

Nettoeinkommen (Verlust:

$-123.57M

KGV:

-0.7997

EPS:

-11.016

Netto-Cashflow:

$-102.89M

1W Leistung:

-5.56%

1M Leistung:

+44.99%

6M Leistung:

+33.79%

1J Leistung:

+44.28%

1-Tages-Spanne:

$8.80

$9.17

1-Wochen-Bereich:

$8.75

$9.831

52-Wochen-Spanne:

$3.51

$10.99

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Firmenname

Karyopharm Therapeutics Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (621)

Telefon

617-658-0600

Adresse

85 WELLS AVENUE, NEWTON, MA

Mitarbeiter

228

Twitter

@Karyopharm

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

KPTI's Discussions on Twitter

Compare KPTI vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KPTI Karyopharm Therapeutics Inc	8.81	167.85M	137.27M	-123.57M	-102.89M	-11.02
VRTX Vertex Pharmaceuticals Inc	460.31	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	765.80	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	724.85	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	322.34	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	291.15	33.09B	5.36B	287.73M	924.18M	2.5229

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-05	Eingeleitet	Cantor Fitzgerald	Overweight
2025-10-13	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-07-16	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-07-11	Fortgesetzt	H.C. Wainwright	Buy
2023-01-19	Eingeleitet	Piper Sandler	Overweight
2022-11-04	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2022-02-09	Hochstufung	JP Morgan	Underweight → Neutral
2021-11-19	Fortgesetzt	Morgan Stanley	Equal-Weight
2021-08-06	Herabstufung	JP Morgan	Overweight → Neutral
2021-08-06	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2021-08-06	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2020-07-02	Eingeleitet	Morgan Stanley	Overweight
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-17	Herabstufung	Wedbush	Outperform → Neutral
2019-07-23	Hochstufung	JP Morgan	Neutral → Overweight
2019-07-05	Bestätigt	H.C. Wainwright	Buy
2019-07-05	Bestätigt	Robert W. Baird	Outperform
2019-03-01	Herabstufung	JP Morgan	Overweight → Neutral
2019-02-28	Bestätigt	BofA/Merrill	Underperform
2019-02-27	Herabstufung	BofA/Merrill	Neutral → Underperform
2019-01-03	Hochstufung	BofA/Merrill	Underperform → Neutral
2018-12-03	Eingeleitet	B. Riley FBR	Buy
2018-11-09	Hochstufung	Wedbush	Neutral → Outperform
2018-05-24	Herabstufung	Wedbush	Outperform → Neutral
2018-04-02	Fortgesetzt	Leerink Partners	Outperform
2017-11-15	Fortgesetzt	H.C. Wainwright	Buy
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2016-09-08	Bestätigt	H.C. Wainwright	Buy
2016-08-30	Hochstufung	Jefferies	Hold → Buy
2016-08-18	Eingeleitet	H.C. Wainwright	Buy
2016-06-28	Eingeleitet	Robert W. Baird	Outperform

Alle ansehen

Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten

Mar 03, 2026

Tax-driven share sale by Karyopharm (KPTI) EVP Mano Michael disclosed - Stock Titan

Mar 03, 2026

Karyopharm (NASDAQ: KPTI) EVP sells shares for tax withholding - Stock Titan

Mar 03, 2026

Karyopharm (KPTI) EVP executes automatic share sale for tax withholding - Stock Titan

Mar 03, 2026

Karyopharm (KPTI) CEO executes automatic 12,361-share sale to cover RSU taxes - Stock Titan

Mar 03, 2026

Automatic tax-sale trims Karyopharm (NASDAQ: KPTI) EVP shareholdings - Stock Titan

Mar 03, 2026

Karyopharm Therapeutics Inc. 8-K Filing and Material Definitive Agreement (February 27, 2026) - Minichart

Mar 03, 2026

KPTI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026

Karyopharm Therapeutics Incon February 27, 2026, company enters second amendment to Credit AgreementSEC filing - marketscreener.com

Mar 03, 2026

Karyopharm Amends Credit Agreement to Extend Liquidity Runway - TipRanks

Mar 03, 2026

According to a filing submitted to the U.S. Securities and Exchange Commission (SEC), Karyopharm Therapeutics Inc. has obtained permission through an amended agreement to defer the payment deadline for certain amounts until September 2026. - Bitget

Mar 03, 2026

Karyopharm Therapeutics Amends Credit Agreement to Defer 2026 Payments, Tied to $25M Equity Raise - TradingView

Mar 03, 2026

[Form 4] Karyopharm Therapeutics Inc. Insider Trading Activity - Stock Titan

Mar 03, 2026

Mar 02, 2026

Karyopharm (KPTI) debt relief and forbearance depend on $25M stock sale - Stock Titan

Mar 02, 2026

Karyopharm Grants 1,450 RSUs to New Hires - National Today

Mar 02, 2026

Pharma company Karyopharm gives 1,450 stock units to two new hires - Stock Titan

Mar 02, 2026

Karyopharm (KPTI) Q4 2025 Earnings Call Transcript - AOL.com

Mar 02, 2026

Feb 28, 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Significant Increase in Short Interest - MarketBeat

Feb 28, 2026

Feb 26, 2026

Karyopharm Therapeutics Target of Unusually Large Options Trading (NASDAQ:KPTI) - MarketBeat

Feb 26, 2026

Feb 25, 2026

KPTI Should I Buy - Intellectia AI

Feb 25, 2026

Feb 23, 2026

Karyopharm Therapeutics Shareholders Approve Plan to Nearly Double Authorized Shares at Special Meeting - Yahoo Finance

Feb 23, 2026

Earnings call transcript: Karyopharm sees 11.8% revenue rise in Q4 2025 - Investing.com Nigeria

Feb 23, 2026

New Highs: Should I set a stop loss on NVAXEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn

Feb 23, 2026

Feb 20, 2026

HC Wainwright Brokers Lift Earnings Estimates for KPTI - MarketBeat

Feb 20, 2026

Can Karyopharm Therapeutics Inc. disrupt its industryJuly 2025 Price Swings & Stepwise Trade Signal Guides - mfd.ru

Feb 20, 2026

Feb 19, 2026

Karyopharm Shareholders Approve Major Authorized Share Increase - TipRanks

Feb 19, 2026

KPTI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Feb 19, 2026

Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade - Zacks Investment Research

Feb 19, 2026

Feb 18, 2026

HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Feb 18, 2026

Aug Movers: Can Karyopharm Therapeutics Inc disrupt its industry2025 Retail Activity & Low Drawdown Momentum Ideas - baoquankhu1.vn

Feb 15, 2026

Analyst Estimates: Here's What Brokers Think Of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Its Full-Year Report - 富途牛牛

Feb 15, 2026

Analysts Have Made A Financial Statement On Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Annual Report - Yahoo Finance

Feb 15, 2026

Feb 14, 2026

Karyopharm Earnings Call: Pivotal Data Amid Cash Squeeze - The Globe and Mail

Feb 14, 2026

Is Karyopharm Therapeutics Inc.’s growth already priced in2025 Market Outlook & Daily Profit Focused Stock Screening - mfd.ru

Feb 14, 2026

Karyopharm Therapeutics Faces Rising Regulatory and Political Risks Amid Supreme Court Limits on FDA Authority - TipRanks

Feb 14, 2026

Karyopharm Therapeutics to Announce Q4 Earnings on February 12 - Intellectia AI

Feb 14, 2026

Feb 13, 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 13, 2026

Karyopharm Therapeutics Inc. SEC 10-K Report - TradingView

Feb 13, 2026

Karyopharm Q4 2025 slides: Revenue growth amid pivotal myelofibrosis readout preparations - Investing.com Australia

Feb 13, 2026

Feb 12, 2026

Karyopharm Therapeutics Inc Shares Rise After Q4 2025 Results - AlphaStreet News

Feb 12, 2026